Market Cap 7.42B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,908,900
Avg Vol 3,697,740
Day's Range N/A - N/A
Shares Out 105.29M
Stochastic %K 43%
Beta N/A
Analysts Strong Sell
Price Target $55.75

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:19 AM
$MTSR is currently trading at $70.5, showing a strong upward momentum with an RSI of 67.08, indicating it is nearing overbought territory. The price is significantly above both the 30-day moving average (MA30) of 59.96 and the 50-day moving average (MA50) of 53.47, suggesting a bullish trend. However, the proximity to the 60-day high of 83.86 raises caution, as it may face resistance near this level. Directional bias is bullish, but with caution due to the RSI nearing overbought levels. Suggested entry is at $70.5, with a stop loss at $65.5 to manage risk. Target 1 is set at $78, just below the 60-day high, and Target 2 at $83, aiming for a breakout above recent resistance. Monitor the price action closely, as a reversal could occur if the RSI exceeds 70. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:41 AM
$MTSR is currently trading at $70.5, showing a strong upward momentum with an RSI of 66.63, indicating it is nearing overbought territory but not yet in it. The price is well above the 30-day MA of 59.34 and the 50-day MA of 52.78, suggesting a bullish trend. The recent high of $83.86 within the last 60 days provides a resistance level, while the low of $30.81 indicates significant support. Directional bias is bullish due to the strong price action and the position above key moving averages. Suggested entry is at $70.5, with a stop loss set at $65.49 (1 ATR below the entry). Targets can be set at $78.00 (near the 60D high) and $83.00 (psychological resistance level). Monitor RSI for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
0 · Reply
himsssss
himsssss Nov. 14 at 9:46 PM
$MRSN moving some $MTSR cash to fund this CVR buyout. atm its $2.77 for $31 dollars over the next 7 years if it pays out.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:01 PM
Hedge Alert Live - Protect Your Portfolio Contract: $MTSR $70.00 Put · NOV 21, 2025 Exp Entry Price: $4.30 - $4.51 Exit Price Target: $7.65 Profit Margin: +78% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Arckiva
Arckiva Nov. 14 at 2:48 PM
$MTSR what’s happening, nothing is showing up
0 · Reply
LLLJJJ
LLLJJJ Nov. 14 at 2:24 PM
$MTSR What will they do this symbol , write off ?
0 · Reply
rick4u
rick4u Nov. 14 at 9:54 AM
$MTSR when pfe will be paid cvr?
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 14 at 9:18 AM
Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO $NVO $MTSR $PFE $LLY https://stocktwits.com/news/equity/markets/novo-nordisk-stock-falls-premarket-as-investors-brace-for-contentious-vote-to-reinstate-former-ceo/cLPQdm5REEu
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 8:20 AM
Hedge Alert Live - Protect Your Portfolio Contract: $MTSR $70.00 Put · NOV 21, 2025 Exp Entry Price: $4.30 - $4.50 Exit Price Target: $6.28 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:14 AM
$MTSR is currently trading at $70.5, showing strong momentum as indicated by an RSI of 66.63, suggesting it is nearing overbought territory but still has room for further gains. The price is above both the 30-day MA (59.34) and the 50-day MA (52.78), indicating a bullish trend. The recent 60-day high of $83.86 provides a significant resistance level, while the 60-day low of $30.81 establishes a strong support base. Given the current context, the directional bias is bullish. Suggested entry point is at $71.00, with a stop loss set at $65.00 to manage risk. Target 1 is set at $80.00, aiming for a significant resistance level, while Target 2 is set at $83.00, just below the recent high. This trade plan leverages the current bullish momentum and MA support levels while managing risk effectively. https://privateprofiteers.com
0 · Reply
Latest News on MTSR
Pfizer Completes Acquisition of Metsera

Nov 13, 2025, 11:26 AM EST - 1 day ago

Pfizer Completes Acquisition of Metsera

PFE


Pfizer to buy Metsera in deal worth up to $10 billion

Nov 10, 2025, 10:30 AM EST - 4 days ago

Pfizer to buy Metsera in deal worth up to $10 billion

PFE


Novo Nordisk shares rise after dropping Metsera bid

Nov 10, 2025, 3:05 AM EST - 5 days ago

Novo Nordisk shares rise after dropping Metsera bid

NVO


Novo CEO says its bid for Metsera is higher

Nov 6, 2025, 2:23 PM EST - 8 days ago

Novo CEO says its bid for Metsera is higher

NVO


Metsera Issues Statement in Response to Litigation Ruling

Nov 5, 2025, 7:17 PM EST - 9 days ago

Metsera Issues Statement in Response to Litigation Ruling


Pfizer preparing to raise its bid for Metsera, WSJ reports

Nov 5, 2025, 5:02 PM EST - 9 days ago

Pfizer preparing to raise its bid for Metsera, WSJ reports

PFE


The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs

Nov 5, 2025, 1:20 PM EST - 9 days ago

The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs


Novo Nordisk CEO: Confident we will close Metsera deal

Nov 5, 2025, 5:39 AM EST - 9 days ago

Novo Nordisk CEO: Confident we will close Metsera deal

NVO


Pfizer and Novo Nordisk both raise bids for Metsera

Nov 4, 2025, 12:18 PM EST - 10 days ago

Pfizer and Novo Nordisk both raise bids for Metsera

NVO PFE


Novo Nordisk says Metsera bid won't raise antitrust issues

Nov 3, 2025, 12:04 PM EST - 11 days ago

Novo Nordisk says Metsera bid won't raise antitrust issues

NVO


Metsera Issues Statement in Response to Litigation

Nov 3, 2025, 11:02 AM EST - 11 days ago

Metsera Issues Statement in Response to Litigation


Pfizer files second lawsuit against Metsera, Novo Nordisk

Nov 3, 2025, 8:07 AM EST - 11 days ago

Pfizer files second lawsuit against Metsera, Novo Nordisk

NVO PFE


Pfizer sues Metsera, Novo Nordisk over breach of merger deal

Oct 31, 2025, 4:43 PM EDT - 14 days ago

Pfizer sues Metsera, Novo Nordisk over breach of merger deal

NVO PFE


Pfizer gets US antitrust clearance for Metsera deal

Oct 31, 2025, 3:55 PM EDT - 14 days ago

Pfizer gets US antitrust clearance for Metsera deal

PFE


Pfizer could hold a Trump card in its bid for Metsera

Oct 31, 2025, 6:02 AM EDT - 14 days ago

Pfizer could hold a Trump card in its bid for Metsera

PFE


Mizuho's Holtz talks what is behind Novo's bid for Metsera

Oct 30, 2025, 6:20 PM EDT - 15 days ago

Mizuho's Holtz talks what is behind Novo's bid for Metsera


PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:19 AM
$MTSR is currently trading at $70.5, showing a strong upward momentum with an RSI of 67.08, indicating it is nearing overbought territory. The price is significantly above both the 30-day moving average (MA30) of 59.96 and the 50-day moving average (MA50) of 53.47, suggesting a bullish trend. However, the proximity to the 60-day high of 83.86 raises caution, as it may face resistance near this level. Directional bias is bullish, but with caution due to the RSI nearing overbought levels. Suggested entry is at $70.5, with a stop loss at $65.5 to manage risk. Target 1 is set at $78, just below the 60-day high, and Target 2 at $83, aiming for a breakout above recent resistance. Monitor the price action closely, as a reversal could occur if the RSI exceeds 70. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:41 AM
$MTSR is currently trading at $70.5, showing a strong upward momentum with an RSI of 66.63, indicating it is nearing overbought territory but not yet in it. The price is well above the 30-day MA of 59.34 and the 50-day MA of 52.78, suggesting a bullish trend. The recent high of $83.86 within the last 60 days provides a resistance level, while the low of $30.81 indicates significant support. Directional bias is bullish due to the strong price action and the position above key moving averages. Suggested entry is at $70.5, with a stop loss set at $65.49 (1 ATR below the entry). Targets can be set at $78.00 (near the 60D high) and $83.00 (psychological resistance level). Monitor RSI for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
0 · Reply
himsssss
himsssss Nov. 14 at 9:46 PM
$MRSN moving some $MTSR cash to fund this CVR buyout. atm its $2.77 for $31 dollars over the next 7 years if it pays out.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:01 PM
Hedge Alert Live - Protect Your Portfolio Contract: $MTSR $70.00 Put · NOV 21, 2025 Exp Entry Price: $4.30 - $4.51 Exit Price Target: $7.65 Profit Margin: +78% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Arckiva
Arckiva Nov. 14 at 2:48 PM
$MTSR what’s happening, nothing is showing up
0 · Reply
LLLJJJ
LLLJJJ Nov. 14 at 2:24 PM
$MTSR What will they do this symbol , write off ?
0 · Reply
rick4u
rick4u Nov. 14 at 9:54 AM
$MTSR when pfe will be paid cvr?
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 14 at 9:18 AM
Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO $NVO $MTSR $PFE $LLY https://stocktwits.com/news/equity/markets/novo-nordisk-stock-falls-premarket-as-investors-brace-for-contentious-vote-to-reinstate-former-ceo/cLPQdm5REEu
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 8:20 AM
Hedge Alert Live - Protect Your Portfolio Contract: $MTSR $70.00 Put · NOV 21, 2025 Exp Entry Price: $4.30 - $4.50 Exit Price Target: $6.28 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:14 AM
$MTSR is currently trading at $70.5, showing strong momentum as indicated by an RSI of 66.63, suggesting it is nearing overbought territory but still has room for further gains. The price is above both the 30-day MA (59.34) and the 50-day MA (52.78), indicating a bullish trend. The recent 60-day high of $83.86 provides a significant resistance level, while the 60-day low of $30.81 establishes a strong support base. Given the current context, the directional bias is bullish. Suggested entry point is at $71.00, with a stop loss set at $65.00 to manage risk. Target 1 is set at $80.00, aiming for a significant resistance level, while Target 2 is set at $83.00, just below the recent high. This trade plan leverages the current bullish momentum and MA support levels while managing risk effectively. https://privateprofiteers.com
0 · Reply
TwongStocks
TwongStocks Nov. 13 at 10:15 PM
$MTSR $PFE NASDAQ corporate action, merger closed https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-605 MTSR shareholders will receive $65.60 and 1 CVR for each share held.
0 · Reply
rick4u
rick4u Nov. 13 at 10:06 PM
$MTSR we have a majority for acquisition at this Price?
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 13 at 6:53 PM
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report $PFE $NVO $MTSR https://stocktwits.com/news/equity/markets/pfizer-ceo-sees-metsera-drugs-hit-market-as-early-as-2028-after-completing-acquisition-report/cLP9fAwREE9
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Nov. 13 at 5:56 PM
$MTSR, enjoy our monies! Love, $PFE shareholders.
1 · Reply
Ro_Patel
Ro_Patel Nov. 13 at 5:07 PM
$MTSR shareholders approve of $PFE takeover in a prelim vote count This will allow Pfizer get back into the fast-growing GLP-1 market Pfizer had discontinued 2 oral GLP-1 candidates - lotiglipron in 2023 & danuglipron in 2025 - due to liver safety concerns, leaving it without a viable in-house obesity drug Metsera's lead candidate, MET-097i, a once-monthly GLP-1 injection had helped patients lose up to 14.1% of their body weight in 2 mid-stage studies & advancing it into late-stage trials. Pfizer expects Metsera's drugs to launch in the 2028, 2029 time frame & potentially help offset upcoming patent losses ($17B-$18B annual rev hit)
1 · Reply
DrStockenstein
DrStockenstein Nov. 13 at 3:08 PM
$MTSR $PFE SHARE PRICE DROPPED 🤣🤣
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 3:01 PM
0 · Reply
Bleu_Magic
Bleu_Magic Nov. 13 at 1:48 PM
$MTSR Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share why not $80.00 per Share? $PFE
1 · Reply
jollylollylondon8
jollylollylondon8 Nov. 13 at 1:13 PM
$MTSR It obviously is not being manipulated, they are just some dumb people who don’t understand that there is real value to the CVR. That CVR is worth $21.5dollars. 
0 · Reply
DrStockenstein
DrStockenstein Nov. 13 at 12:02 PM
$MTSR Who thinks The price is being manipulated... 🤡
0 · Reply
jollylollylondon8
jollylollylondon8 Nov. 13 at 9:09 AM
$MTSR Early morning sellers clearly don’t understand the value of the CVR; Goldman and Guggenheim put the closing value at $72.40 ish.. should move towards 72.40 before close tonight
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:21 AM
$MTSR is currently trading at $70.8, showing strong momentum as indicated by an RSI of 66.68, suggesting it's nearing overbought territory but still has room for upward movement. The price is significantly above the 30-day MA of 58.09 and the 50-day MA of 51.39, indicating a bullish trend. The recent high of $83.86 presents a key resistance level, while the low of $29.19 provides a solid support base. For a trade plan, consider entering at $71.50 to capitalize on potential upward momentum. Set a stop loss at $66.00 to manage risk. Target 1 can be set at $80.00, approaching the 60D high, and Target 2 at $83.00, just below the recent high. This plan leverages the current bullish indicators while accounting for volatility with an ATR of 4.96. Monitor the RSI closely for any signs of reversal as it approaches overbought levels. https://privateprofiteers.com
1 · Reply